XELOXA

Regimen

Experimental
CAPOX/XELOX (capecitabine + oxaliplatin Q3W × 8 cycles)
Control
Bolus fluorouracil/leucovorin (Mayo Clinic or Roswell Park regimen)

Population

Stage III colon cancer after curative resection (N=1,886), adjuvant CAPOX vs bolus FU/LV.

Key finding

3-year DFS: XELOX (CAPOX) 70.9% vs FU/FA 66.5% (HR 0.80, P=.0045); 5-year OS: 77.6% vs 74.2% (HR 0.87, P=.15, not significant). Established CAPOX as equivalent alternative to FOLFOX for stage III adjuvant therapy.

Source: PMID 21383294

Timeline

    Guideline citations

    • NCCN Colon (p.67)
    • NCCN Rectal (p.57)